Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations

by Dapporto, Francesca , Marchi, Serena , Lorusso, Eleonora , Manenti, Alessandro , Piccini, Giulia , Andreano, Emanuele , Paciello, Ida , Trombetta, Claudia Maria , Leonardi, Margherita , Decaro, Nicola , Rappuoli, Rino , Lovreglio, Piero , Benincasa, Linda , Stufano, Angela , Pierleoni, Giulio , Buonvino, Nicola , Ruello, Antonella , Viviani, Simonetta , Molesti, Eleonora , Bombardieri, Emilio , Montomoli, Emanuele

in 631/250/255/2514 / 631/250/590/2293 / Antibody Formation / Antibody response / Biology / Biomedical and Life Sciences / Combined vaccines / Coronaviruses / COVID-19 / COVID-19 - prevention & control / COVID-19 vaccines / Cross-protection / Humans / Immune response / Infections / Life Sciences / Membrane Glycoproteins - metabolism / mRNA / SARS-CoV-2 - genetics / Severe acute respiratory syndrome coronavirus 2 / Spike Glycoprotein, Coronavirus - genetics / Spike protein / Vaccination / Vaccines / Viral Envelope Proteins - genetics

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations

2022

Confirm

Do you wish to request the book?

Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations

Dapporto, Francesca,

Marchi, Serena,

Lorusso, Eleonora,

Manenti, Alessandro,

Piccini, Giulia,

Andreano, Emanuele,

Paciello, Ida,

Trombetta, Claudia Maria,

Leonardi, Margherita,

Decaro, Nicola,

Rappuoli, Rino,

Lovreglio, Piero,

Benincasa, Linda,

Stufano, Angela,

Pierleoni, Giulio,

Buonvino, Nicola,

Ruello, Antonella,

Viviani, Simonetta,

Molesti, Eleonora,

Bombardieri, Emilio,

Montomoli, Emanuele

2022

Overview

The SARS-CoV-2 Omicron variant has rapidly replaced the Delta variant of concern. This new variant harbors worrisome mutations on the spike protein, which are able to escape the immunity elicited by vaccination and/or natural infection. To evaluate the impact and susceptibility of different serum samples to the Omicron variant BA.1, samples from COVID-19 patients and vaccinated individuals were tested for their ability to bind and neutralize the original SARS-CoV-2 virus and the Omicron variant BA.1. COVID-19 patients show the most drastic reduction in Omicron-specific antibody response in comparison with the response to the wild-type virus. Antibodies elicited by a triple homologous/heterologous vaccination regimen or following natural SARS-CoV-2 infection combined with a two-dose vaccine course, result in highest neutralization capacity against the Omicron variant BA.1. Overall, these findings confirm that vaccination of COVID-19 survivors and booster dose to vaccinees with mRNA vaccines is the correct strategy to enhance the antibody cross-protection against Omicron variant BA.1. Antibodies elicited by a triple homologous or heterologous vaccination regimen or following natural SARS-CoV-2 infection combined with a two-dose vaccine course, result in highest neutralization capacity against the Omicron variant BA.1.

Share this book

Add to My Shelf

Publisher

Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio

Subject

/ Biology

/ Biomedical and Life Sciences

/ Combined vaccines